The members of our scientific advisory board bring deep expertise across the core areas that drive the development of our innovative CAR-NK cell therapies.
Catherine Blish, MD, PhD
Associate Dean for Basic and Translational Research and Professor of Medicine and Immunology at the Stanford University School of Medicine.
Catherine Bollard, MD
Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at The George Washington University and Director of the Center for Cancer and Immunology Research at the Children’s National Research Institute at Children’s National Hospital; scientific co-founder of Catamaran Bio.
Yvonne Chen, PhD
Associate Professor, Department of Microbiology, Immunology, and Molecular Genetics, Department of Chemical and Biomolecular Engineering, University of California, Los Angeles.
Gianpietro Dotti, MD
Professor of Microbiology and Immunology, Co-Leader Immunology Program and Director of Cellular Immunotherapy Program of Lineberger Comprehensive Cancer Center, University of North Carolina.
Timothy Harris, PhD
Venture Partner, SV Health Investors; Senior Scientific Consultant, Repertoire Immune Medicines; co-founder of Catamaran Bio and Chairman of the SAB.
Christopher Klebanoff, MD
Assistant Member, Memorial Sloan Kettering Cancer Center (MSKCC) Human Oncology and Pathogenesis Program (HOPP); Member Investigator, MSKCC Center for Cell Engineering and the Parker Institute for Cancer Immunotherapy.
Lewis Lanier, PhD
Chairman, Department of Microbiology and Immunology, University of California, San Francisco; Co-Lead Cancer Immunology and Immunotherapy Program UCSF Cancer Center.
Branden Moriarity, PhD
Associate Professor in the Department of Pediatrics, Division of Hematology/Oncology at the University of Minnesota; scientific co-founder of Catamaran Bio.
Eric Yvon, PhD
Associate Professor, Department of Medicine, Hematology/Oncology, Director of Stem Cell Transplantation and Cell Therapy Laboratories, The George Washington University Cancer Center.